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OBJECTIVES: To examine the relationship between in-
dicators of inflammation and the incidence of mobility
limitation in older persons.
DESIGN: Prospective cohort study: the Health, Aging and
Body Composition Study.
SETTING: Pittsburgh, Pennsylvania, and Memphis, Ten-
nessee.
PARTICIPANTS: A total of 2,979 men and women, aged
70 to 79, without mobility limitation at baseline.
MEASUREMENTS: Serum levels of interleukin (IL)-6,
tumor necrosis factor alpha (TNFa), and C-reactive protein
(CRP) and soluble cytokine receptors (IL-2sR, IL-6sR,
TNFsR1, TNFsR2) were measured. Mobility limitation
was assessed and defined as reporting difficulty or inability
to walk one-quarter of a mile or to climb 10 steps during
two consecutive semiannual assessments over 30 months.
RESULTS: Of the 2,979 participants, 30.1% developed
incident mobility limitation. After adjustment for con-
founders (demographics, prevalent conditions at baseline,
body composition), the relative risk (RR) of incident
mobility limitation per standard deviation (SD) increase
was 1.19 (95% confidence interval (CI)51.10–1.28) for
IL-6, 1.20 (95% CI51.12–1.29) for TNFa, and 1.40 (95%
CI5 1.18–1.68) for CRP. The association between inflam-
mation and incident mobility limitation was especially
strong for the onset of more severe mobility limitation and
when the levels of multiple inflammatory markers were
high. When persons with baseline or incident cardiovas-
cular disease events or persons who were hospitalized
during study follow-up were excluded, findings remained
similar. In a subset (n5499), high levels of the soluble
receptors IL2sR and TNFsR1 (per SD increase: RR51.23
(95% CI5 1.04–1.46) and RR51.28 (95% CI51.04–
1.57), respectively) were also associated with incident
mobility limitation.
CONCLUSION: Findings suggest that inflammation is
prognostic for incident mobility limitation over 30 months,
independent of cardiovascular disease events and incident
severe illness. J Am Geriatr Soc 52:1105–1113, 2004.
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Inflammation is a necessary response of the immunesystem to different stimuli such as infection and injury,
resulting in elevated production of cytokines and acute-
phase proteins, but when inflammation is chronic, it
appears to have detrimental effects. Increased levels of
inflammatory markers, such as interleukin-6 (IL-6) and C-
reactive protein (CRP), have been observed in the presence
of acute and chronic conditions, including atherosclerosis,1
cerebrovascular disease,2–4 coronary heart disease,5–7 con-
gestive heart failure (CHF),8 and arthritis.9,10 In addition,
cytokines may contribute to decreased skeletal muscle mass
in old age.11 Because of the link between cytokines and
several disabling conditions, it has been hypothesized that
an elevated inflammatory response could be the common
root of the pathophysiological mechanism leading to an
age-related decline in physical function. Indeed, evidence
linking inflammation to function is growing. In a cross-
sectional study, serum levels of IL-6 were positively
correlated with disability independent of prevalent disease.9
In a 4-year longitudinal examination of nondisabled older
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people, high levels of IL-6 predicted the onset of disability.12
Although various inflammatory markers such as IL-6, CRP,
and tumor necrosis factor alpha (TNFa) are correlated with
each other, the relative importance of these markers as
predictors of physical decline has not been established.
The soluble receptors of proinflammatory cytokines
may also play an important role in the deleterious effects of
the inflammation process. There is some evidence that
stimuli causing cytokine levels to rise may also induce
shedding of soluble cytokine receptors in an attempt to
dampen the inflammatory response. Thus, elevated levels of
soluble receptors may represent a more prolonged or severe
underlying inflammatory state.13,14 In addition, because
soluble cytokine receptors are generally more stable in the
circulation over time than cytokines,15,16 they might be
more reliable markers of chronic inflammation. Soluble
cytokine receptors are elevated in the presence of various
chronic conditions. For instance, circulating levels of TNFa
soluble receptors (TNFsR1 and TNFsR2) are more strongly
correlated with severity of CHF than TNFa,17,18 with a high
level of TNFsR1 being associated with a poorer prognosis
of CHF.19 In arthritis, serum levels of soluble interleukin-2
receptor (IL-2sR) are positively correlated with disease
activity and functional status.10 Despite this evidence, the
relationship between soluble cytokine receptors and physi-
cal function in a general older population has not been
explored.
The present study examines the association between
severalmarkersof inflammation, includingCRP,IL-6,TNFa,
and the soluble receptors IL-2sR, IL-6sR, TNFsR1, and
TNFsR2 with the onset of mobility limitation in a large
sample of well-functioning black and white older men and
women. Mobility limitation is one of the main outcomes in
the Health, Aging and Body Composition (Health ABC)
Study because of the need to identify risk factors at a stage
of age-related decline that would be amenable to preventive
interventions. More severe impairment (e.g., defined by
activity of daily living disability) has more often been
examined in previous large studies, but although an
important outcome, it represents a stage of decline that
may be too far advanced to be amenable to intervention.
METHODS
Study Population
Data from the Health ABC Study, a prospective cohort
study of the influence of changes in body composition and
health conditions on physiological and functional changes,
were used. Well-functioning participants, aged 70 to 79,
were recruited from April 1997 to June 1998. Participants
were drawn from a sample of Medicare beneficiaries
residing in the areas around Pittsburgh, Pennsylvania, and
Memphis, Tennessee. To be eligible, participants had to
report no difficulty walking one-quarter of a mile, climbing
10 steps, or performing basic activities of daily living.
Participants also had to be free of life-threatening illness
and plan to remain in the geographic area for at least 3
years. A total of 3,075 men and women, of whom 42%
were black, were included in the study. Data on inflamma-
tory markers were missing for 31 participants, and 65 had
missing outcome data, leaving 2,979 participants for the
present analyses. All participants signed an informed
written consent approved by the institutional review boards
of the clinical sites.
Measurements
Baseline assessments consisted of a questionnaire adminis-
tered at a home visit and a subsequent clinic visit. During
this visit, blood samples were drawn in the morning after an
overnight fast (median time was 9:19 a.m. interquartile
range was from 8:49 a.m. to 9:52 a.m.). After processing,
serum aliquots were placed in cryovials, and shipped frozen
to the Health ABC Core Laboratory at the University of
Vermont.
Inflammatory Markers
Levels of IL-6, TNFa, CRP, and soluble receptors of IL-6
(IL-6sR), IL-2 (IL-2sR), and TNFa (TNFsR1 and TNFsR2)
were assessed. Serum levels of soluble receptors were only
available for a randomly selected subcohort of 499 persons.
Cytokines and soluble cytokine receptors levels were
measured in duplicate using enzyme-linked immunosorbent
assay kits (R&D Systems, Minneapolis, MN). The detect-
able limit for IL-6 (using HS600 Quantikine kit) was
0.10 pg/mL, for TNFa (using HSTA50 kit) was 0.18 pg/mL,
for IL-6sR (using DR600 kit) was 6.5 pg/mL, for TNFsR1
(using DRT100 kit) was 3 pg/mL, for TNFsR2 (using
DRT200 kit) was 1 pg/mL, and for IL-2sR (using DR2A00
kit) was 10 pg/mL. Serum levels of CRP were also measured
in duplicate using enzyme-linked immunosorbent assay
based on purified protein and polyclonal anti-CRP anti-
bodies (Calbiochem, San Diego, CA). The CRP assay was
standardized according to the World Health Organization
First International Reference Standard with a sensitivity of
0.08mg/mL. Assays of blind duplicates collected for 150
participants yielded an average interassay coefficient of
variation of 10.3% for IL-6, 8.0% for CRP, and 15.8% for
TNFa. Circulating IL-6 and CRP levels obtained from one
time point have been shown to be reproducible and
representative over extended time periods.20
Mobility Limitation
The occurrence of mobility limitation over the first 30
months of study follow-up was determined at the annual
study assessment visits (12 and 24 months after baseline) or
during telephone follow-up assessments (6, 18, and 30
months after baseline). During all assessments, participants
were asked whether they experienced difficulty (no, a little,
some, a lot, or inability) in walking one-quarter of a mile or
in climbing 10 steps. Incident mobility limitation was
considered to be present if a person reported any difficulty
or inability to walk one-quarter of a mile or climb 10 steps
at two consecutive semiannual follow-up assessments. The
requirement that limitations needed to be present at two
consecutive assessments selects more chronic and severe
functional limitation, and therefore this outcome is a more
reliable indicator of a clinically relevant change in
functional status. A special Health ABC Study committee
that considered additionally available information such as
reason for missing a study contact (severe illness, in nursing
home) and proxy information for those who died adjudi-
cated the incidence of mobility limitation. In additional
analyses, the effect of severity of mobility limitation was
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explored by distinguishing (1) the incidence of moderate
mobility limitation as defined by at least a little or some
difficulty walking one-quarter of a mile or climbing 10 steps
at two consecutive assessments and (2) severe mobility
limitation as defined by a lot of difficulty or inability to
walk one-quarter of a mile or climb 10 steps at two
consecutive assessments. Subjects who developed moderate
and severe mobility limitation during study follow-up were
classified as having the severe outcome.
Covariates
Sociodemographics included age, race, education, and
study site. Smoking status (yes/no) was assessed in the
baseline interview. Total body fat mass was determined
using dual energy x-ray absorptiometry (Hologic 4500 A,
Hologic Inc., Waltham, MA). Even though participants
reported no functional limitation at baseline, there was still
likely to have been a range of physical capacity within the
sample. To adjust for this, a performance score was
included that summarizes, on a scale from 0 (poor) to 12
(good performance), a person’s performance on a 6-meter
walk test, a standing balance test, and five repetitions of
chair rises.21 The baseline presence of lung disease, heart
disease (including myocardial infarction, angina pectoris,
and CHF), stroke, diabetes mellitus, cancer, and osteoar-
thritis was adjudicated using standardized algorithms
considering self-report, medication use, and some clinic
assessments. All medications regularly taken in the previous
2 weeks were recorded and coded according to the Iowa
Drug Information System code. Using this drug inventory,
the daily use of nonsteroidal antiinflammatory drugs
(NSAIDs) and systemic corticosteroids was assessed.
Incident cardiovascular disease (CVD) events over the 30
months of follow-upwere defined using conclusive evidence
for myocardial infarction, stroke, CHF, or angina pectoris
from hospitalization or death records that were adjudicated
according to criteria decided on by the Health ABC death
and disease adjudication committee. Finally, plasma levels
of total cholesterol, creatinine, and albumin were measured
using a Johnson and Johnson Vitros 950 analyzer (New
Brunswick, NJ).
Statistical Analyses
Differences in proportions andmeans of covariates between
persons with and without incident mobility limitation were
assessed using chi-square and t test statistics, respectively.
Because serum levels of inflammatory markers were not
normally distributed (except for IL-6sR), median values
with 25th to 75th percentile ranges were reported, and
nonparametric Mann-Whitney U tests were used to
compare serum levels across outcome groups. Subsequently,
Cox proportional hazards regression models were used to
evaluate the association between inflammatory markers
and time to incident mobility limitation. Persons surviving
with no evidence of incident mobility limitation were
censored at the last study visit (approximately 30 months
after baseline), those dying with no evidence of incident
mobility limitation were censored at the time of their death,
and those lost to follow-up were censored after their last
interview. Relative risks (RRs) and 95% confidence
intervals (CIs) were adjusted for the covariates found to
be associated with incident mobility limitation status.
Continuous levels (after log-transformation to normalize
the distribution) and tertiles of inflammatory marker levels
were used in the analyses. To facilitate results interpreta-
tion, risks were expressed per population standard devia-
tion (SD) of the log value of the inflammatory markers.
Because high levels of two or more inflammatory
markers likely represent a more specific indicator of
systemic inflammation than a high level of just one
inflammatory marker,22,23 additional analyses were con-
ducted with a composite inflammation index, calculated
as the number of inflammatory marker levels within
the highest tertile. Finally, to establish whether the effect
of inflammatory markers on the incidence of mobility
limitation could be due to incident CVD events or to more
general serious health events, the analyses were repeated
after exclusion of persons with baseline or incident CVD
events or persons with a hospitalization during study
follow-up.24
RESULTS
The mean age  SD of the study sample was 73.6  2.9;
51.8% were women, and 41.5% were black. Of the initial
2,979 participants, 898 (30.1%) had incident mobility
limitation during the 30 months of follow-up. Of the
persons with incident mobility limitation, 321 (35.7%)
fulfilled the severe mobility limitation definition (a lot of
difficulty or inability to walk one-quarter of a mile or climb
10 steps at two consecutive assessments), and 577 (64.3%)
had moderate mobility limitation. Population characteris-
tics according to incident mobility limitation status are
reported in Table 1. Participants with incident mobility
limitation were older and more likely to be female, black,
and less educated than those who did not develop mobility
limitation. In addition, these persons had more body fat and
more diseases at study baseline, poorer Established Popula-
tion for Epidemiologic Studies of the Elderly (EPESE)
performance scores, lower albumin and higher creatinine
levels, and higher usage of NSAIDs and corticosteroids than
those without incident mobility limitation.
Spearman correlations between cytokines and soluble
receptors were calculated. A stronger correlation existed
between IL-6 and CRP (r5 0.47, Po.001) than between
IL-6 and TNFa (r50.27, Po.001) or TNFa and CRP
(r5 0.13, Po.001). In the subset of 499 persons who had
soluble cytokine receptors measured, TNFsR1 and TNFsR2
showed a strong intercorrelation (r5 0.84), and both were
also highly correlated with IL-2sR (TNFsR1, r5 0.64; and
TNFsR2, r50.66) and TNFa (TNFsR1, r50.58; and
TNFsR2, r5 0.61) (all Po.001). Overall, IL-6sR showed
the lowest correlations with other cytokines and soluble
cytokine receptors; the correlation between IL-6sR and IL-6
was only 0.07 (P5.10).
Persons who developed incident mobility limitation
had significantly higher serum levels of IL-6, TNFa, and
CRP at baseline (Table 1). For instance, the median IL-6
level was 1.70mg/L for those without incident mobility
limitation and 2.18mg/L for those with incident mobility
limitation. Within the subgroup of 499 persons for whom
soluble cytokine receptors were assessed, the levels of IL-
2sR, TNFsR1, and TNFsR2, but not IL-6sR, were
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significantly higher in those who developed incident
mobility limitation during follow-up.
Table 2 shows the results of the Cox proportional
hazard analyses between inflammatory markers and in-
cident mobility limitation, adjusting for variables that
showed a significant univariate association with onset of
mobility limitation (age, race, education, total fat mass,
EPESE performance score, lung disease, heart disease,
stroke, diabetes mellitus, cancer, osteoarthritis, NSAID
use, corticosteroid use, albumin, and creatinine). In these
adjusted analyses, higher levels of CRP, IL-6, and TNFa
were all significantly associated with an increased risk of
incident mobility limitation but appeared to be stronger for
IL-6 and CRP than for TNFa. This increased risk was
consistent for (log-transformed) continuous levels and for
tertiles of the markers. Compared with the lowest tertile,
the RR of incident mobility limitation for the highest tertile
was 1.40 (95% CI51.18–1.68) for CRP, 1.65 (95%
CI51.37–1.98) for IL-6, and 1.18 (095% CI5 .99–1.41)
for TNFa. When analyses were repeated separately for the
incidence of moderate versus severe mobility limitation,
markers of inflammation showed the strongest association
(highest risk ratios) for the severe outcome of mobility
limitation. For incident moderate mobility limitation, there
was no association with TNFa.
Whether the associations betweenCRP, IL-6, andTNFa
and incident mobility limitation were different for men and
women and for blacks andwhites was examined by entering
interaction terms in the multivariate Cox proportional
hazards analyses. None of the interaction terms for sex or
race were statistically significant (P4.10), indicating that
the association between inflammatory markers and incident
mobility limitation was consistent for sex and racial groups.
It has been suggested that a composite index of
inflammatory markers may increase the specificity for
ongoing inflammation and better predict physical decline
than high levels of a single inflammatory markers.22,23
Some evidence for this suggestion was found when an
interaction term for CRP by IL6 by TNFa was added
along with the individual markers in a multivariate Cox
Table 1. Baseline Characteristics According to Incident Mobility Limitation Status
Characteristic
No Incident
Mobility Limitation
Incident Mobility
Limitation
P-valuen5 2,081 n5 898
Age, mean  SD 73.5  2.9 73.9  2.9 o.001
Female, % 48.0 60.7 o.001
Black, % 37.3 51.2 o.001
Memphis site, % 49.8 50.2 .85
Education, % o.001
oHigh school 21.5 33.4
High school 31.9 34.6
Postsecondary education 46.6 32.0
Smoker, %
Past 48.8 47.6 .35
Current 11.6 13.5
Total body fat, kg, mean  SD 23.1  7.8 27.1  9.9 o.001
Established Population for Epidemiologic Studies
of the Elderly performance score, mean  SD
10.3  1.4 9.4  1.9 o.001
Lung disease, % 12.7 21.8 o.001
Cardiovascular disease, % 15.5 27.7 o.001
Stroke, % 5.7 10.2 o.001
Diabetes mellitus, % 12.2 21.2 o.001
Cancer, % 19.8 16.4 .03
Osteoarthritis, % 11.3 20.6 o.001
Albumin, mg/dL, mean  SD 4.0  0.3 3.9  0.3 o.001
Total cholesterol, mean  SD, mg/dL 202.4  37.6 204.6  40.6 o.001
Creatinine, mean  SD, mg/dL 1.04  0.3 1.11  0.6 o.001
Use of nonsteroidal antiinflammatory drugs, % 63.2 70.3 o.001
Use of corticosteroids, % 2.8 4.6 .01
C-reactive protein, mg/L, median (IQR) 1.51 (0.94–2.73) 2.31 (1.18–4.00) o.001
IL-6, pg/mL, median (IQR) 1.70 (1.17–2.56) 2.18 (1.50–3.38) o.001
TNF-a, pg/mL, median (IQR) 3.10 (2.40–3.94) 3.36 (2.58–4.39) o.001
IL-2sR, mg/ml, median (IQR)w 1.22 (0.91–1.56) 1.36 (1.05–1.73) .004
IL-6sR, mg/ml, median (IQR)w 33.4 (28.8–40.5) 33.6 (28.7–39.8) .97
TNFsR1, mg/ml, median (IQR)w 1.48 (1.29–1.79) 1.65 (1.40–2.09) o.001
TNFsR2, mg/ml, median (IQR)w 3.36 (2.96–3.91) 3.68 (3.02–4.67) .001
Based on chi-square statistics for categorical variables and t test or nonparametric Mann-Whitney statistics for continuous variables.
w Soluble cytokine receptor information available only for a random sample of 499 persons.
IL5 interleukin; TNF5 tumor necrosis factor; IQR5 interquartile range.
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proportional hazard analyses, and a statistically significant
interaction between the inflammatory markers was found
(coefficient50.087, P5.001). Consequently, the three
inflammatory markers were combined into a composite
index. The risk of incident mobility limitation was found to
be especially high in persons who had multiple high levels
(upper tertile) of inflammatory markers (P-trend for
composite indexo.001). Persons with one (n5882,
cumulative incidence of incident mobility disability (cum
inc)5 30.6%) or two (n5563, cum inc537.5%) high
inflammatory markers showed greater risk of incident
mobility limitation of 1.32 (95% CI51.10–1.59) and 1.37
(95% CI51.12–1.68), respectively, than those with no
high levels (n51,045, cum inc5 20.7%), but for persons
with a high serum level for all three markers (n5222, cum
inc5 51.8%), the risk of incident mobility limitation was
1.84 (95% CI51.44–2.53). A similar gradient of risk
across the composite inflammation index was present for
the incidence of moderate and severe mobility limitation
but strongest for the severe form of mobility limitation
(Figure 1). For this outcome, the risk was somewhat
elevatedFbut not statistically significantFwhen one
inflammatory marker level was high (RR51.38, 95%
CI50.99–1.92) but was much elevated when two or three
inflammatory marker levels were high (RR51.90, 95%
CI51.35–2.67 and RR52.23, 95% CI51.48–3.36,
respectively).
Because inflammatory markers are associated with the
prevalence and onset of CVD events,24 additional analyses
were conducted to determine whether the occurrence of
CVD events in the persons who developed mobility
limitation could explain the findings. As expected, an
incident CVD event during the 30 months of follow-up
occurred more often in those with incident mobility
limitation than in those without incident mobility limita-
tion (13.0% vs 7.1%, Po.001), but when the persons who
had baseline or incident CVD events (n5841) were
excluded, the risk of mobility limitation across levels of
inflammatory markers remained similar to the risk de-
scribed before and remained statistically significant (Table
3). To explore the effect of general serious health events, all
817 persons with incident hospitalization during the 30-
month study follow-up (37.1% of those with incident
mobility limitation vs 22.2% without incident mobility
limitation, Po.001) were then excluded. Again, after
excluding those who underwent hospitalizations, the
association between inflammatory markers and the in-
cidence of mobility limitation remained statistically sig-
nificant (Table 3).
In the subset of 499 participants in whom soluble
cytokine receptors were measured, higher levels of IL-2sR
and TNFsR1 were significantly associated with an in-
creased incidence of mobility limitation (Table 4). These
associations were especially strong for the incidence of
severe mobility limitation. Within the subset, TNFsR1 and
TNFsR2 appeared to be better predictors of incident
mobility limitation than TNFa, because the 2 log
likelihood test showed more predictive value for the models
with TNFsR1 (25121.5, df5 14) and TNFsR2
(25 116.9, df514) than for the model with TNFa
(25 111.6, df5 14). Models with calculated ratios for
TNFa with its soluble receptors did not improve the
prediction of incident mobility limitation (25111.8,
df514 for TNFa/TNFsR1 and 25115.2, df514 for
TNFa/TNFsR2) compared with the models containing just
the TNFa receptors.
Table 2. Risk of Incident Mobility Limitation by Tertile According to Level of Inflammatory Markers
Inflammatory Marker/Tertile
Incident Mobility Limitation
Incident Mobility Limitation by Severity Level
Moderate Severe
Cumulative Incidence [Adjusted Risk Ratio] (95% Confidence Interval)
CRP, mg/L
Per SDw increase 30.2 [1.19] (1.10–1.28) 19.4 [1.17] (1.06–1.29) 10.8 [1.23] (1. 09–1.39)
Low (o1.17) 22.2 [1] 15.6 [1] 6.7 [1]
Middle (1.17–2.54) 26.9 [1.05] (0.88–1.26) 17.2 [1.00] (0.80–1.24) 9.7 [1.22] (0.89–1.68)
High (42.54) 41.4 [1.40] (1.18–1.68) 25.3 [1.33] (1.08–1.65) 16.1 [1.74] (1.28–2.38)
IL-6, pg/mL
Per SDw increase 30.1 [1.20] (1.12–1.29) 19.3 [1.18] (1.08–1.29) 10.8 [1.24] (1.10–1.40)
Low (o1.43) 19.8 [1] 13.5 [1] 6.3 [1]
Middle (1.43–2.42) 30.6 [1.34] (1.11–1.62) 19.7 [1.33] (1.06–1.67) 10.9 [1.48] (1.07–2.05)
High (42.42) 40.2 [1.65] (1.37–1.98) 24.8 [1.65] (1.31–2.07) 15.4 [1.82] (1.32–2.52)
TNF-a, pg/mL
Per SDw increase 29.9 [1.09] (1.01–1.18) 19.4 [1.07] (0.98–1.18) 10.5 [1.16] (1.03–1.32)
Low (o2.69) 25.0 [1] 17.2 [1] 7.8 [1]
Middle (2.69–3.72) 28.7 [1.09] (0.91–1.30) 19.6 [1.10] (0.90–1.37) 9.1 [1.11] (0.80–1.53)
High (43.72) 36.1 [1.18] (0.99–1.41) 21.6 [1.13] (0.91–1.41) 14.5 [1.40] (1.03–1.90)
Note: High is defined as upper tertile score.
Adjusted for age, sex, race, education, total fat mass, Established Population for Epidemiologic Studies of the Elderly performance score, lung disease, heart disease,
stroke, diabetes mellitus, cancer, arthritis, nonsteroidal antiinflammatory drug use, corticosteroid use, albumin, and creatinine.
w0.98 for (log) C-reactive protein (CRP), 0.67 for (log) interleukin-6 (IL-6), and 0.42 for (log) tumor necrosis factor-a (TNFa).
SD5 standard deviation.
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DISCUSSION
The study findings indicate that, in well-functioning older
persons, high serum levels of the inflammatory markers
CRP, IL-6, and TNFa predict an increased incidence of
mobility limitation during a 30-month follow-up period.
The relationships were stronger for the more severe
mobility limitation (as defined by a lot of difficulty or
inability to walk one-quarter of a mile or climb 10 steps at
two consecutive semiannual assessments) than for moder-
ate mobility limitation (those who reported at least a little
difficulty at two consecutive assessments). The associations
remained after excluding those persons with baseline or
incident CVD or those persons who were hospitalized
during follow-up, suggesting that CVD or the occurrence of
general serious health events in those with high levels of
inflammatory markers are not likely to explain the findings
simply. In addition, persons who had high levels of all three
markers (CRP, IL-6, and TNFa) showed the highest
incidence of mobility limitation.
How could inflammation affect physical function over
time? Despite good evidence that circulating levels of
inflammatory markers are indicators of atherosclerosis25,26
and CVD,27 the analyses excluding persons who had a CVD
event suggest that cardiovascular health is not the only
pathway linking inflammation and physical decline. It
could be that inflammatory markers are indicators of
disease activity in conditions such as rheumatoid arthritis,
systemic lupus erythematosus, or chronic infections, but
because the participants were well-functioning, healthy
individuals at baseline, it is again unlikely that these
conditions fully explain the observed relationships in the
study.
This epidemiological study confirmed an association
between inflammatory markers and the onset of mobility
limitation in older persons, but it does not permit for the
determination of whether this association is causal. For
example, it cannot be excluded that inflammation is a
surrogate indicator for disease burden and consequently is
associated with an increased risk of mobility limitation, but
the literature shows some potentially causal mechanisms by
which inflammation could lead to disability. Experiments in
rodent models show that administration of IL-6 or TNFa
increases skeletal muscle protein breakdown, decreases the
rate of protein synthesis, reduces the total skeletal muscle
amino acid concentration, and causes sarcopenia.28–31
Consequently, inflammation has been hypothesized to cause
loss of muscle mass and strength directly, which leads to
mobility limitation.32 Using cross-sectional data from the
Health ABC Study, some investigators confirmed a relation-
ship between IL-6 and TNFa and lower muscle mass and
lower muscle strength.33
Another possibility is that elevated levels of inflamma-
tory markers reflect an escape of the inflammatory process
from normal biological regulation due to aging and
therefore indicate biological frailty, which may directly
affect (or simply reflect) physical function. Studies have
shown that, with increasing age, levels of inflammatory
markers rise into the measurable range.9 Also, systemic
inflammation has shown to be associated with lower
hemoglobin levels,34 which could also explain part of the
link with physical decline. Anemia has shown to be a strong
risk factor for physical decline,34,35 even in those without
disease, which may partly be due to its concurrent
symptoms of fatigue or its physiological effects, such as
loss of muscle strength through muscle deoxygenation.36
Finally, high levels of inflammatory markers were recently
associated with poorer pulmonary function in older
persons.37
To the authors’ knowledge, this study is the first to
explore the association between serum levels of soluble
cytokine receptors and incident mobility limitation. Despite
the fact that information on soluble cytokine receptors was
only available for 499 participants and analyses should be
considered exploratory, significant results were observed.
Higher serum levels of IL-2sR and TNFsR1 increased
the risk of incident persistent mobility limitation, and a
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P-trend <.001  
Figure 1. Adjusted (for age, race, education, total fat mass,
Established Population for Epidemiologic Studies of the Elderly
performance score, lung disease, heart disease, stroke, diabetes
mellitus, cancer, arthritis, nonsteroidal anti-inflammatory drugs
use, corticosteroid use, albumin, and creatinine) relative risk for
incident moderate and severe mobility limitation according to
the composite inflammation index counting the number of high
levels (within highest tertile) of three inflammatory markers (C-
reactive protein, interleukin-6, and tumor necrosis factor alpha).
Dots indicate the adjusted relative risk; vertical lines indicate the
95% confidence intervals. RR5 relative risk.
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suggestive (but nonsignificant) trend was found for
TNFsR2. For the soluble TNF receptors, this finding is
not surprising, considering the strong intercorrelation
between TNF soluble receptor levels and TNFa levels.
High levels of soluble cytokine receptors may indicate the
body’s attempt to control inflammation and therefore
reflect a more chronic, systemic state of inflammation. In
addition, an advantage of themeasurement of soluble TNFa
receptors is that they are more stable in the circulation than
TNFa and thus more accurately detected with a single
blood draw.15,16 This could indicate that the predictive
value for incident mobility limitation may even be stronger
for serum levels of soluble TNFa receptors than for TNFa
levels, which these results support in part. In the subsample
of 499 persons, better predictive values were found for
incidentmobilitylimitationforthemodelswithsolubleTNFa
receptors than for the model with TNFa (see Results), and
in line with this, RRs per SD increase were higher for the
Table 4. Adjusted Risk of Incident Mobility Limitation According to Cytokine Receptor Levels in a Subcohort of 499
Persons
Soluble Cytokine Receptor, mg/mL
Incident Mobility Limitation
Incident Mobility Limitation by
Severity Level
Moderate Severe
Relative Risk (95% Confidence Interval)
IL-2sR per SDw increase in log(IL-2sR) 1.23 (1.04–1.46) 1.10 (0.87–1.39) 1.50 (1.14–1.96)
IL-6sR per SDw increase in IL-6sR 0.93 (0.78–1.11) 0.94 (0.75–1.18) 0.93 (0.68–1.27)
TNFsR1 per SDw increase in log(TNFsR1) 1.28 (1.04–1.57) 1.26 (0.93–1.70) 1.52 (1.11–2.10)
TNFsR2 per SDw increase in log(TNFsR2) 1.13 (0.95–1.35) 1.16 (0.90–1.51) 1.26 (0.93–1.72)
Adjusted for age, sex, race, education, total fat mass, Established Population for Epidemiologic Studies of the Elderly performance score, lung disease, heart disease,
stroke, diabetes mellitus, cancer, arthritis, nonsteroidal antiinflammatory drugs use, corticosteroid use, albumin, and creatinine.
w0.42 for interleukin (IL)-2sR, 8.52 for IL-6sR, 0.30 for tumor necrosis factor soluble receptor (TNFsR) 1 and 0.46 for TNFsR2.
(IL)-2sR, soluble interleukin-2 receptor; IL-6sR a soluble interleukin-6 receptor; TNFsR2 tumor necrosis factor soluble receptor; and
SD5 standard deviation.
Table 3. Risk of Incident Mobility Limitation without Cardiovascular Disease (CVD) Events or Hospitalizations During
Follow-Up According to Levels of Inflammatory Markers
Inflammatory Marker
Excluding Persons with Baseline or
Incident CVD Events
Excluding Persons with Any
Incident Hospitalizations
Adjusted Relative Risk (95% Confidence Interval)
C-reactive protein (CRP)
Per SD increase in (log) CRP 1.15 (1.04–1.27) 1.31 (1.18–1.45)
Lowest tertile (o1.17) 1 1
Middle tertile (1.17–2.54) 0.93 (0.74–1.16) 1.09 (0.86–1.39)
Highest tertile (42.54) 1.21 (0.98–1.51) 1.68 (1.34–2.11)
Interlukin-6 (IL-6)
Per SD increase in (log)IL-6 1.23 (1.12–1.35) 1.25 (1.14–1.36)
Lowest tertile (o1.43) 1 1
Middle tertile (1.43–2.42) 1.23 (0.97–1.55) 1.46 (1.15–1.85)
Highest tertile (42.42) 1.64 (1.30–2.08) 1.80 (1.42–2.29)
Tumor necrosis factor-a (TNF-a)
Per SD increase in (log)TNF-a 1.09 (0.99–1.20) 1.13 (1.03–1.24)
Lowest tertile (o2.69) 1 1
Middle tertile (2.69–3.72) 1.06 (0.84–1.32) 1.23 (0.98–1.54)
Highest tertile (43.72) 1.20 (0.95–1.51) 1.29 (1.03–1.63)
Composite inflammation index
No high inflammatory markers 1 1
1 of 3 markers are highw 1.30 (1.03–1.64) 1.43 (1.13–1.81)
2 of 3 markers are highw 1.37 (1.06–1.76) 1.55 (1.19–2.01)
All 3 markers are highw 1.79 (1.29–2.48) 2.07 (1.51–2.85)
Adjusted for age, sex, race, education, total fat mass, Established Population for Epidemiologic Studies of the Elderly performance score, lung disease, heart disease,
stroke, diabetes mellitus, arthritis, nonsteroidal antiinflammatory drugs use, corticosteroid use, albumin, and creatinine.
wHigh level is defined as within highest tertile group.
IL5 interleukin; CRP5C-reactive protein; TNF5 tumor necrosis factor.
SD5 standard deviation.
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soluble TNFa receptor levels (RR51.28 for TNFsR1 and
RR51.13 for TNFsR2) than for TNFa level (RR51.10).
This finding is consistent with findings that serum levels of
soluble TNFa receptors were more strongly associated with
certain disease processes, such as atherosclerosis25 and
CHF,17 than TNFa levels.
The finding of a strong link between IL-2sR level and
incident mobility limitation is also novel. High levels of IL-
2sR are directly correlated with increased T and B cell and
immune system activation,38 and the current study showed
a high correlation with TNFsR1 and TNFsR2 levels. In
contrast, IL-6sR showed low correlations with other
soluble cytokine receptors and with serum IL-6 levels and
did not show an association with incident mobility
limitation.
A composite measure of inflammation, combining
information on CRP, IL-6, and TNFa, identified persons
with a high incidence of future physical decline. About 19%
of the well-functioning sample had high levels (upper
tertile) on two, and 8% had high serum levels on three
inflammatory markers. These persons had the highest risk
for an increased incidence of (severe) mobility limitation.
These findings are consistent with previous work showing
an increased mortality risk if more than one inflammatory
marker was elevated.22,23 The use of a combined measure
for inflammation likely increases the specificity for inflam-
mation status, that is, the probability that persons with low
levels of two or three inflammatory markers have no
ongoing subclinical inflammation, and will reduce non-
differential misclassification.
This study has several strengths. First, there was
information on not just one but multiple markers of
inflammation. Second, the sample consisted of a randomly
selected community-based cohort in which loss to follow-
up over time was limited. Third, the study was designed to
study the transition tomobility limitation and used frequent
contacts to assess changes in limitations, which increases
the validity of functional change assessment.39 Weaknesses
of the study are that there was only limited information on
the severity of baseline diseases and that inflammatory
markers were only assessed once, whichmakes it impossible
to explore the importance of change in inflammation before
the onset of mobility limitation. Also, the main outcome
was based on self-report, although comparable self-
reported limitation outcomes have been shown to be
reliable indicators of clinically relevant changes in health
such as hospitalization, institutionalization, and death.40–42
In summary, this study supports the prognostic value of
CRP, IL-6, TNFa, and the soluble receptors IL-2sR and
TNFsR1 for incident mobility limitation in a relatively
healthy cohort of older men and women. The analyses
suggest that such a link is not purely due to CVD events or
general serious health events but is likely to represent a
general down-spiral pathway involving multiple pathophy-
siological mechanisms.
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